Core Viewpoint - The Trump administration is considering the creation of a direct-to-consumer prescription drug platform, potentially named "TrumpRx," to allow patients to purchase discounted medications directly from pharmaceutical companies [1][2]. Group 1: Direct-to-Consumer Model - The proposed "TrumpRx" website aims to connect patients with pharmaceutical companies, enabling them to search for specific drugs and access purchasing channels directly, bypassing traditional pharmacy routes [1]. - Major pharmaceutical companies have responded positively to the direct-to-consumer (DTC) model, with Eli Lilly launching a remote healthcare platform for cheaper weight loss medications and Pfizer and Bristol-Myers Squibb introducing a DTC platform for their blood thinner, Eliquis [3]. Group 2: Pharmaceutical Industry Response - In July, Trump sent letters to 17 major pharmaceutical companies demanding immediate price reductions for existing drugs under the federal Medicaid program and ensuring that new drug prices align with international market levels [2]. - The "TrumpRx" initiative is a specific response to Trump's request for companies to create platforms for direct sales of popular medications that benefit from high insurance discounts [2]. Group 3: Broader Drug Pricing Strategies - The U.S. government is implementing various regulatory measures to reshape the pharmaceutical market, including stricter enforcement of advertising regulations on television and social media to curb demand-inflating marketing practices [4]. - Trump has threatened to impose tariffs of up to 250% on imported drugs to encourage companies to relocate more production lines back to the U.S., indicating a multifaceted approach to drug pricing control [4].